Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria

Sho, T; Suda, G; Ogawa, K; Shigesawa, T; Suzuki, K; Nakamura, A; Ohara, M; Umemura, M; Kawagishi, N; Natsuizaka, M; Nakai, M; Morikawa, K; Furuya, K; Baba, M; Ito, J; Yamamoto, Y; Kobayashi, T; Meguro, T; Saga, A; Miyagishima, T; Terasita, K; Takagi, T; Kamiyama, T; Taketomi, A; Sakamoto, N

Suda, G (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kita Ku, North 15,West 7, Sapporo, Hokkaido 0608638, Japan.

HEPATOLOGY RESEARCH, 2020; 50 (8): 966

Abstract

Aim This study aimed to determine the efficacy and safety of lenvatinib for patients with unresectable hepatocellular carcinoma (HCC) who did not meet......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索